Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Clinical Cancer Research - Tập 17 Số 8 - Trang 2110-2119 - 2011
Emilie P. Buddingh1,2,3,4,5, Marieke L. Kuijjer1,2,3,4,5, R.A.J. Duim1,2,3,4,5, Horst Bürger1,2,3,4,5, Konstantin Agelopoulos1,2,3,4,5, Ola Myklebost1,2,3,4,5, Massimo Serra1,2,3,4,5, Fredrik Mertens1,2,3,4,5, Pancras C.W. Hogendoorn1,2,3,4,5, Arjan C. Lankester1,2,3,4,5, Anne‐Marie Cleton‐Jansen1,2,3,4,5
1Authors' Affiliations: 1Department of Pediatrics; 2Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 3Institute of Pathology; 4Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany; 5Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 6Laboratory of Experimental Oncology Research, Istituto Ortopedico Rizzoli, Bologna, Italy; and 7Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
2Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
3Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
4Institute of Pathology
5Laboratory of Experimental Oncology Research, Istituto Ortopedico Rizzoli, Bologna, Italy

Tóm tắt

AbstractPurpose: High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence in adolescence. Overall survival (OS) of patients with resectable metastatic disease is approximately 20%. The exact mechanisms of development of metastases in osteosarcoma remain unclear. Most studies focus on tumor cells, but it is increasingly evident that stroma plays an important role in tumorigenesis and metastasis. We investigated the development of metastasis by studying tumor cells and their stromal context.Experimental Design: To identify gene signatures playing a role in metastasis, we carried out genome-wide gene expression profiling on prechemotherapy biopsies of patients who did (n = 34) and patients who did not (n = 19) develop metastases within 5 years. Immunohistochemistry (IHC) was performed on pretreatment biopsies from 2 additional cohorts (n = 63 and n = 16) and corresponding postchemotherapy resections and metastases.Results: A total of 118/132 differentially expressed genes were upregulated in patients without metastases. Remarkably, almost half of these upregulated genes had immunological functions, particularly related to macrophages. Macrophage-associated genes were expressed by infiltrating cells and not by osteosarcoma cells. Tumor-associated macrophages (TAM) were quantified with IHC and associated with significantly better overall survival (OS) in the additional patient cohorts. Osteosarcoma samples contained both M1- (CD14/HLA-DRα positive) and M2-type TAMs (CD14/CD163 positive and association with angiogenesis).Conclusions: In contrast to most other tumor types, TAMs are associated with reduced metastasis and improved survival in high-grade osteosarcoma. This study provides a biological rationale for the adjuvant treatment of high-grade osteosarcoma patients with macrophage activating agents, such as muramyl tripeptide. Clin Cancer Res; 17(8); 2110–9. ©2011 AACR.

Từ khóa


Tài liệu tham khảo

Raymond, 2002, Conventional osteosarcoma, World Health Classification of Tumours: Pathology and genetics of tumours of soft tissue and bone., 264

Lewis, 2007, Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup, J Natl Cancer Inst, 99, 112, 10.1093/jnci/djk015

Bacci, 2006, Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy—15-year experience in 789 patients treated at a single institution, Cancer, 106, 1154, 10.1002/cncr.21724

Bielack, 2002, Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols, J Clin Oncol, 20, 776, 10.1200/JCO.2002.20.3.776

Marina, 2010, International collaboration is feasible in trials for rare conditions: the EURAMOS experience, Cancer Treat Res, 152, 339, 10.1007/978-1-4419-0284-9_18

Meyers, 2008, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the children's oncology group, J Clin Oncol, 26, 633, 10.1200/JCO.2008.14.0095

Kleinerman, 1992, Unique histological-changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (Cgp-19835A Lipid), Cancer Immunol Immunother, 34, 211, 10.1007/BF01741788

Hagemann, 2006, Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype, J Immunol, 176, 5023, 10.4049/jimmunol.176.8.5023

Lee, 2008, Prognostic significance of macrophage infiltration in leiomyosarcomas, Clin Cancer Res, 14, 1423, 10.1158/1078-0432.CCR-07-1712

Lissbrant, 2000, Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival, Int J Oncol, 17, 445

Volodko, 1998, Tumour-associated macrophages in breast cancer and their prognostic correlations, Breast, 7, 99, 10.1016/S0960-9776(98)90065-0

Jensen, 2009, Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on cancer stage I/II melanoma, J Clin Oncol, 27, 3330, 10.1200/JCO.2008.19.9919

van Dongen, 2009, Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors, Int J Cancer, 127, 899, 10.1002/ijc.25113

Sica, 2008, Macrophage polarization in tumour progression, Seminars Cancer Biol, 18, 349, 10.1016/j.semcancer.2008.03.004

Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014

Mosser, 2008, Exploring the full spectrum of macrophage activation, Nat Rev Immunol, 8, 958, 10.1038/nri2448

Kim, 2008, High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer, Br J Cancer, 98, 1118, 10.1038/sj.bjc.6604256

Forssell, 2007, High macrophage infiltration along the tumor front correlates with improved survival in colon cancer, Clin Cancer Res, 13, 1472, 10.1158/1078-0432.CCR-06-2073

Jaiswal, 2010, Macrophages as mediators of tumor immunosurveillance, Trends Immunol, 31, 212, 10.1016/j.it.2010.04.001

Mohseny, 2009, Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2, J Pathol, 219, 294, 10.1002/path.2603

Ottaviano, 2010, Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort, Genes Chromosomes Cancer, 49, 40, 10.1002/gcc.20717

Rozeman, 2005, Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas, J Pathol, 205, 476, 10.1002/path.1723

2005, R: a language and environment for statistical computing, reference index version 2.9.0.

Du, 2007, nuID: a universal naming scheme of oligonucleotides for Illumina, Affymetrix, and other microarrays, Biol Direct, 2, 16, 10.1186/1745-6150-2-16

Lin, 2008, Model-based variance-stabilizing transformation for Illumina microarray data, Nucleic Acids Res, 36, e11, 10.1093/nar/gkm1075

Gentleman, 2004, Bioconductor: open software development for computational biology and bioinformatics, Genome Biol, 5, R80, 10.1186/gb-2004-5-10-r80

Du, 2008, lumi: a pipeline for processing Illumina microarray, Bioinformatics, 24, 1547, 10.1093/bioinformatics/btn224

Kauffmann, 2009, arrayQualityMetrics—a bioconductor package for quality assessment of microarray data, Bioinformatics, 25, 415, 10.1093/bioinformatics/btn647

Smyth, 2004, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Stat Appl Genet Mol Biol, 3, 1, 10.2202/1544-6115.1027

Buddingh, 2010, Prognostic factors in pulmonary metastasized high-grade osteosarcoma, Pediatr Blood Cancer, 54, 216, 10.1002/pbc.22293

Lin, 2006, Macrophages regulate the angiogenic switch in a mouse model of breast cancer, Cancer Res, 66, 11238, 10.1158/0008-5472.CAN-06-1278

Hagemann, 2008, “Re-educating” tumor-associated macrophages by targeting NF-kappa B, J Exp Med, 205, 1261, 10.1084/jem.20080108

Sinha, 2005, Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease, J Immunol, 174, 636, 10.4049/jimmunol.174.2.636

Buhtoiarov, 2007, Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides, Immunology, 120, 412, 10.1111/j.1365-2567.2006.02517.x

Ojalvo, 2009, High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors, Am J Pathol, 174, 1048, 10.2353/ajpath.2009.080676

Martinez, 2006, Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression, J Immunol, 177, 7303, 10.4049/jimmunol.177.10.7303

Zitvogel, 2008, Immunological aspects of cancer chemotherapy, Nat Rev Immunol, 8, 59, 10.1038/nri2216

Kono, 2008, How dying cells alert the immune system to danger, Nat Rev Immunol, 8, 279, 10.1038/nri2215

Meyers, 2005, Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate, J Clin Oncol, 23, 2004, 10.1200/JCO.2005.06.031

Kurzman, 1995, Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, 1, 1595

Geddes, 2009, Unleashing the therapeutic potential of NOD-like receptors, Nat Rev Drug Discov, 8, 465, 10.1038/nrd2783

Ochi, 2004, Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles, Int J Oncol, 24, 647

Salas, 2009, Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2, Int J Cancer, 125, 851, 10.1002/ijc.24457

Man, 2005, Expression profiles of osteosarcoma that can predict response to chemotherapy, Cancer Res, 65, 8142, 10.1158/0008-5472.CAN-05-0985

Mintz, 2005, An expression signature classifies chemotherapy-resistant pediatric osteosarcoma, Cancer Res, 65, 1748, 10.1158/0008-5472.CAN-04-2463

Cleton-Jansen, 2009, Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways, Br J Cancer, 101, 2064, 10.1038/sj.bjc.6605482

Thông tin
Thông tin xuất bản

Clinical Cancer Research

Tập 17 Số 8

2110-2119

Thông tin tác giả